Aprea Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Aprea is a clinical-stage precision-oncology company with no approved products or product-sale revenue. Its lead candidate, ATRN-119, is in an early-stage clinical trial; APR-1051 is its WEE1 inhibitor candidate.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Grant revenue | $0.38 million | None |
| Research and development | $1.60 million | $1.26 million; up $0.34 million |
| General and administrative | $1.93 million | $3.37 million; down $1.44 million |
| Total operating expenses | $3.53 million | $4.62 million; down $1.09 million |
| Net loss | $2.81 million | $4.38 million |
| Net loss per share, basic and diluted | $0.67 | $1.34 |
| Net cash used in operating activities | $3.94 million | $2.98 million |
Reduced G&A, primarily due to lower personnel costs and severance expense, drove the smaller net loss. R&D increased mainly because of APR-1051 IND-enabling work. Grant revenue was from the National Cancer Institute. Product margins are not applicable because Aprea has no product sales.
At March 31, cash and cash equivalents were $32.37 million, versus $21.61 million at year-end 2023; restricted cash was $0.04 million. Current assets were $33.07 million and current liabilities $2.97 million. The balance sheet reports no debt. Accumulated deficit was $310.89 million. Management estimates existing cash will fund operations and capital needs into the third quarter of 2025, subject to assumptions that may prove inaccurate.
Financing provided $14.71 million net cash in Q1, principally from the March private placement: approximately $16.0 million gross proceeds and $1.3 million of fees and offering costs. Operating cash use increased year over year despite the lower net loss, largely because of changes in operating assets and liabilities.
Material changes, outlook, and risks
- In March, Aprea sold 1,687,712 common shares and issued pre-funded warrants and Tranche A and B warrants. Potential future cash proceeds from warrant exercises were estimated at up to approximately $18 million before fees; none had been exercised by March 31. The financing increased the common share count and creates potential dilution.
- The FDA cleared APR-1051’s IND in March. Management expected first-patient enrollment in its Phase 1 dose-escalation study in Q2 2024, a study update in Q4 2024, open-label safety/efficacy data in Q2 2025, and a recommended Phase 2 dose in the second half of 2025.
- For ATRN-119, the first four dose cohorts were complete and enrollment continued. Management anticipated a Phase 1 readout in Q1 2025. These are plans and estimates, not assured outcomes.
- Aprea expects expenses and operating losses to rise as development advances. It says additional financing will be needed; if funding is unavailable, it may reduce, delay, or stop development. The company has no committed external funding source.
- Key risks include early-stage clinical uncertainty, patient enrollment and regulatory delays, dependence on third parties and a single manufacturer, financing and dilution risk, and intellectual-property and competition risks. The filing reports no material legal proceedings and no provision for contingent losses.
- Management reported effective disclosure controls as of March 31, 2024, and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether reported cash and the stated runway remain consistent with actual quarterly operating cash use and the timing and cost of planned trials.
- Progress against ATRN-119 and APR-1051 enrollment, data-readout, and dose-selection timelines, including any delays or safety findings.
- The terms, exercise conditions, and potential dilution from the private-placement warrants, and whether any warrant proceeds are received.
- Whether grant funding continues and whether Aprea secures additional financing or collaborations before its projected cash runway ends.
- Whether manufacturing capacity, trial execution, or regulatory requirements change the company’s development plans or cash needs.